提出日:
報告基準日:
PRIMARY DOCUMENT
提出日:
報告基準日:
ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT
提出日:
報告基準日:
AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY
提出日:
報告基準日:
ADMISSION OF FURTHER SECURITIES TO TRADING
提出日:
報告基準日:
TOTAL VOTING RIGHTS
提出日:
報告基準日:
ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT
提出日:
報告基準日:
TRIXEO APPROVED IN EU FOR ASTHMA
提出日:
報告基準日:
KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP
提出日:
報告基準日:
ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC
提出日:
報告基準日:
DIRECTOR/PDMR SHAREHOLDING
提出日:
報告基準日:
DIRECTOR/PDMR SHAREHOLDING
提出日:
報告基準日:
DIRECTOR/PDMR SHAREHOLDING
提出日:
報告基準日:
UPDATE ON SERENA-4 PHASE III TRIAL
提出日:
報告基準日:
OWNERSHIP DOCUMENT
提出日:
報告基準日:
IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG
提出日:
報告基準日:
ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER
提出日:
報告基準日:
ADMISSION OF FURTHER SECURITIES TO TRADING
提出日:
報告基準日:
TOTAL VOTING RIGHTS
提出日:
報告基準日:
ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING
提出日:
報告基準日:
ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC
提出日:
報告基準日:
DIRECTORATE CHANGE
提出日:
報告基準日:
ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY
提出日:
報告基準日:
TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG
提出日:
報告基準日:
TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS
提出日:
報告基準日:
ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING
提出日:
報告基準日:
DIRECTOR/PDMR SHAREHOLDING
提出日:
報告基準日:
ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER
提出日:
報告基準日:
UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL
提出日:
報告基準日:
TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG
提出日:
報告基準日:
PRIMARY DOCUMENT
提出日:
報告基準日:
ADMISSION OF FURTHER SECURITIES TO TRADING
提出日:
報告基準日:
TOTAL VOTING RIGHTS
提出日:
報告基準日:
DATROWAY APPROVED IN EU FOR TNBC
提出日:
報告基準日:
FORM 6-K
提出日:
報告基準日:
UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA
提出日:
報告基準日:
SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS
提出日:
報告基準日:
ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER
提出日:
報告基準日:
ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR
提出日:
報告基準日:
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL
提出日:
報告基準日:
OWNERSHIP DOCUMENT